 CENTOGENE CNTG, a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced that it will open a new laboratory in Hamburg, Germany acquiring the former laboratory facilities and equipment of Provecs Medical GmbH, a company formerly active in cancer immunotherapy. The new laboratory, which is opening in April 2020, will enable increased testing capacity for the COVID-19 virus and will also result in the expansion of laboratory capacity for the Companys diagnostic testing of rare genetic diseases. 